


Highlights of This Issue 829


REVIEWS

- 831 **Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma**
Lisa Vincenz, Richard Jäger, Michael O'Dwyer, and Afshin Samali

- 844 **Cyclooxygenase-2, Epidermal Growth Factor Receptor, and Aromatase Signaling in Inflammation and Mesothelioma**
Barbara Nuvoli and Rossella Galati

CHEMICAL THERAPEUTICS

- 853 **Bcl-2/Bcl-x_L Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models**
 Nguyen Tan, Maureen Wong, Michelle A. Nannini, Rebecca Hong, Leslie B. Lee, Stephen Price, Karen Williams, Pierre Pascal Savy, Peng Yue, Deepak Sampath, Jeffrey Settleman, Wayne J. Fairbrother, and Lisa D. Belmont


- 865 **RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib**
 Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim, and Yung-Jue Bang

- 878 **The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair**
Yun Dai, Shuang Chen, Maciej Kmiecik, Liang Zhou, Hui Lin, Xin-Yan Pei, and Steven Grant

- 890 **The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non-Small Cell Lung Cancer Growth**
Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon Pitts, Naimeh Kamranpour, Amrita J. Desai, Wylie Hosmer, Susan Ide, Emin Avsar, Michael Rugaard Jensen, Cornelia Quadt, Manway Liu, Steven M. Dubinett, and Dennis J. Slamon

- 901 **Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an *In Vivo* Model of NRAS-Mutant Melanoma**
H. Eirik Haarberg, Kim H.T. Paraiso, Elizabeth Wood, Vito W. Rebecca, Vernon K. Sondak, John M. Koomen, and Keiran S.M. Smalley

- 913 **A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of *In Vivo* Antitumor Activities**
Yoshiko Awazu, Kazuhide Nakamura, Akio Mizutani, Yuichi Kakoi, Hidehisa Iwata, Seiji Yamasaki, Naoki Miyamoto, Shinichi Imamura, Hiroshi Miki, and Akira Hori

- 925 **Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion**
 Jing Wang, Natalie W. Pursell, Maria Elena S. Samson, Ruzanna Atoyian, Anna W. Ma, Abdelkader Selmi, Wanlu Xu, Xiong Cai, Maurizio Voi, Pierre Savagner, and Cheng-Jung Lai

- 937 **Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer**
Shili Xu, Fedora Grande, Antonio Garofalo, and Nouri Neamati

- 950 **Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities *In Vitro* and *In Vivo***
Hua Xie, Mee-Hyun Lee, Feng Zhu, Kanamata Reddy, Zunnan Huang, Dong Joon Kim, Yan Li, Cong Peng, Do Young Lim, Soouk Kang, Sung Keun Jung, Xiang Li, Haitao Li, Weiya Ma, Ronald A. Lubet, Jian Ding, Ann M. Bode, and Zigang Dong

959 **Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer**

Michael A. Batey, Yan Zhao, Suzanne Kyle, Caroline Richardson, Andrew Slade, Niall M.B. Martin, Alan Lau, David R. Newell, and Nicola J. Curtin

1016 **Downregulation of Hepatoma-Derived Growth Factor Contributes to Retarded Lung Metastasis via inhibition of Epithelial-Mesenchymal Transition By Systemic POMC Gene Delivery in Melanoma**



Han-En Tsai, Guei-Sheung Liu, Mei-Lang Kung, Li-Feng Liu, Jian-Ching Wu, Chia-Hua Tang, Ching-Hui Huang, San-Cher Chen, Hing-Chung Lam, Chieh-Shan Wu, and Ming-Hong Tai

LARGE MOLECULE THERAPEUTICS

968 **Milatuzumab-SN-38 Conjugates for the Treatment of CD74⁺ Cancers**

Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold, and David M. Goldenberg

1026 **Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals**

Xiaohai Wang, Soo Ok Lee, Shujie Xia, Qi Jiang, Jie Luo, Lei Li, Shuyuan Yeh, and Chawnshang Chang

979 **Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu**

Yu Cao, Khalid A. Mohamedali, John W. Marks, Lawrence H. Cheung, Walter N. Hittelman, and Michael G. Rosenblum

1038 **Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis**

Dongsheng Gu, Hailan Liu, Gloria H. Su, Xiaoli Zhang, Helen Chin-Sinex, Helmut Hanenberg, Marc S. Mendonca, Harlan E. Shannon, E. Gabriela Chiorean, and Jingwu Xie

CANCER THERAPEUTICS INSIGHTS

992 **BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer**

Bercin Kutluk Cenic, Katherine T. Ostapoff, David E. Gerber, and Rolf A. Brekken

1049 **Hrk Mediates 2-Methoxyestradiol-Induced Mitochondrial Apoptotic Signaling in Prostate Cancer Cells**

Inik Chang, Shahana Majid, Sharanjot Saini, Mohd S. Zaman, Soichiro Yamamura, Takeshi Chiyomaru, Varahram Shahryari, Shinichiro Fukuhara, Guoren Deng, Rajvir Dahiya, and Yuichiro Tanaka

1002 **Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer**

Maike Ihnen, Christine zu Eulenburg, Teodora Kolarova, Jing Wei Qi, Kanthinh Manivong, Meenal Chalukya, Judy Dering, Lee Anderson, Charles Ginther, Alexandra Meuter, Boris Winterhoff, Siân Jones, Victor E. Velculescu, Natarajan Venkatesan, Hong-Mei Rong, Sugandha Dandekar, Nitin Udar, Fritz Jänicke, Gerrit Los, Dennis J. Slamon, and Gottfried E. Konecny

1060 **SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ**

Monica Brenca, Sabrina Rossi, Erica Lorenzetto, Elena Piccinin, Sara Piccinin, Francesca Maria Rossi, Alberto Giuliano, Angelo Paolo Dei Tos, Roberta Maestro, and Piergiorgio Modena

1073 **Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair**

Kushtrim Kryeziu, Ute Jungwirth, Mir Alireza Hoda, Franziska Ferk, Siegfried Knasmüller, Claudia Karnthaler-Benbakka, Christian R. Kowol, Walter Berger, and Petra Heffeter

1085 | **Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs**
Stefania Stella, Elena Tirrò, Enrico Conte, Fabio Stagno, Francesco Di Raimondo, Livia Manzella, and Paolo Vigneri

1099 | **Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP**
Xuemei Xie, Chandra Bartholomeusz, Ahmed A. Ahmed, Anna Kazansky, Lixia Diao, Keith A. Baggerly, Gabriel N. Hortobagyi, and Naoto T. Ueno

1122 | **HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors**
Elicia Penuel, Congfen Li, Vaishali Parab, Luciana Burton, Kyra J. Cowan, Mark Merchant, Robert L. Yauch, Premal Patel, Amy Peterson, Garret M. Hampton, Mark R. Lackner, and Priti S. Hegde

1131 | **ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer**
Rebekah L. Zinn, Eric E. Gardner, Luigi Marchionni, Sara C. Murphy, Irina Dobromilskaya, Christine L. Hann, and Charles M. Rudin

COMPANION DIAGNOSTICS & CANCER BIOMARKERS

1112 | **Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease**
Lai-Ping Zhong, Dong-Wang Zhu, William N. William Jr, Ying Liu, Jie Ma, Cheng-Zhe Yang, Xiao Yang, Li-Zhen Wang, Jiang Li, Jeffrey N. Myers, J. Jack Lee, Chen-Ping Zhang, and Zhi-Yuan Zhang

TOOLS AND TECHNOLOGIES


1140 | **Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model**
Holly A.F. Stessman, Linda B. Baughn, Aaron Sarver, Tian Xia, Raamesh Deshpande, Aatif Mansoor, Susan A. Walsh, John J. Sunderland, Nathan G. Dolloff, Michael A. Linden, Fenghuang Zhan, Siegfried Janz, Chad L. Myers, and Brian G. Van Ness

AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

Composite immunofluorescence of HER2-positive human tumor (BT474 M1) xenografts. Tumor sections from mice treated with saline (controls) were stained for tumor cell nuclei (blue) using Hoechst 33342 dye and blood vessels were stained (red) using anti-mouse CD31 antibody. Tumors from the group treated with fusion construct showed tumor-specific delivery of human granzyme B and upregulation of TUNEL-positive tumor cells compared with controls. For details, see article by Cao and colleagues on page 979.



Molecular Cancer Therapeutics

12 (6)

Mol Cancer Ther 2013;12:829-1150.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/12/6>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/12/6>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.